Drug Type Antibody drug conjugate (ADC), Liposomal Drug |
Synonyms NV105 |
Target |
Action inhibitors |
Mechanism CD99 inhibitors(CD99 molecule (Xg blood group) inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ewing Sarcoma | Preclinical | United States | 01 Mar 2026 | |
| Glioblastoma Multiforme | Preclinical | United States | 01 Mar 2026 |






